Sugi Predict

Sugi Predict / Compounds / SCHEMBL20096845

SCHEMBL20096845

SCHEMBL20096845

O=C(O)c1cccc2c1CC1(CCN(Cc3ccc(Cl)cc3)C1=O)C2

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC11 Q96DB2 10/20 0.66
▸ RIPK1 Q13546 1/20 0.40
▸ PTGER4 P35408 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ DRD3 P35462 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20096840 0.89 HDAC11 (0.83) HDAC11HDAC6
SCHEMBL20132808 0.88 HDAC11 (0.64) HDAC11PTGER4HDAC6HPGDALDH1A1
SCHEMBL24462842 0.83 HDAC11 (0.55) HDAC11RIPK1HDAC6HPGDALDH1A1
SCHEMBL20096696 0.83 HDAC11 (0.80) HDAC11PTGER4HDAC6
SCHEMBL20096922 0.82 HDAC11 (0.83) HDAC11RIPK1HDAC6
SCHEMBL20132867 0.81 HDAC11 (0.72) HDAC11PTGER4HDAC6
SCHEMBL20096998 0.81 HDAC11 (0.64) HDAC11RIPK1ALDH1A1MEN1KMT2A
SCHEMBL29754239 0.81 HDAC11 (0.83) HDAC11PTGER4HDAC6
SCHEMBL20096690 0.81 HDAC11 (0.83) HDAC11PTGER4HDAC6
SCHEMBL20096738 0.81 HDAC11 (0.80) HDAC11PTGER4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479807-B2 Methods using HDAC11 inhibitors VALO HEALTH, INC. (US) 2025-11-25 — — US disclosed
US-20220235018-A1 METHODS USING HDAC11 INHIBITORS Valo Health, LLC 2022-07-28 — — US disclosed
US-11345672-B2 Methods using HDAC11 inhibitors VALO HEALTH, INC. (US) 2022-05-31 — — US disclosed
US-20200079744-A1 METHODS USING HDAC11 INHIBITORS VALO HEALTH, INC. 2020-03-12 — — US disclosed
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS Valo Health, LLC 2019-03-21 — — US disclosed
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS Valo Health, LLC 2019-03-21 — — US disclosed
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS VALO HEALTH, INC. 2019-03-21 — — US disclosed
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS VALO HEALTH, INC. 2019-03-21 — — US disclosed
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-05-10 — — US disclosed
WO-2018075959-A1 METHODS USING HDAC11 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2018-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079744-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-11345672-B2 Methods using HDAC11 inhibitors HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-12479807-B2 Methods using HDAC11 inhibitors HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885
US-20220235018-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885RIPK1 1900/4885PTGER4 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.